Sheik, we get it. Because you happen to have doubled your money...

Sheik, we get it. Because you happen to have doubled your money in Analytica (ALT) since you invested, you think Michael Monsour is a genius. Enough already.

Let's look at the facts: Monsour became Chairman of Analytica on 28 March 2006 when its closing share price was 2.2c. By November/December 2007, it got down to 1.2c, then rose to as high as 7.3c in November 2008. It is now 3c.

This is a penny dreadful, a company with a market cap of $16 million.

The purchasers of tens of millions of ALT shares on the market at prices far higher than the current 3c level would not agree with your assessment of Monsour.

You can attribute the doubling of your investment in ALT to luck, or your skill in timing if you like, but giving Monsour the credit is nonsense.

As for Monsour's record as a CBio director, he supported to the bitter end a wasteful regime led by Jones which burned $112 million of our cash. And what was the result? The key trial which the company had staked everything on failed to reach its primary endpoint. CBio shareholders should be grateful that all the previous directors and management responsible for this stuff-up have resigned - so a new Board and management can have a chance to turn the company's fortunes around.

You claim that none of the current CBio Board members are "credible". This is incredible!

The only people you are kidding would be yourself and your supporter COLINK60.

CBio's Chairman Dr Ralph Craven is also the Chairman of Ergon Energy, which if it were listed on the ASX would be in the top 30 stocks by market capitalisation. In his role as Deputy Chairman of Arrow Energy until the company's sale to Shell and PetroChina, he made a lot of money for his shareholders.

CBio shareholders are fortunate indeed to have such a respected, skilled and experienced independent company director to be the Chairman of our company, in charge of turning it around and getting it back on track.

You claim that as a result of the Board changes CBio has had a "100% reduction in deals". The truth is CBio never had a deal with any pharma company; Novo Nordisk simply had an option to negotiate a deal which they declined to exercise.

You claim that the reason Novo Nordisk did not exercise its option was because the "Shareholder Action Group made claims suggesting that the previous Board were involved in something dodgy".

I cannot recall any such statement by the SAG on its website or in its letters to shareholders. I challenge you to provide evidence of this, but doubt that you can.

There is no way in the world if the science had ticked all the boxes at this time that Novo Nordisk would have walked away from doing a deal with CBio, particularly with former NN senior executive Dr Kalland and fellow European director Dr Lonngren still on the Board at the time.

The new CBio Board now has to come up with a strategy to prove the drug works with a commercially viable method of delivery in one or more auto-immune diseases - such as RA, lupus, MS and psoriasis - and then we will have a drug which will command a far better deal than we would have got if Novo Nordisk had exercised its option.

It was heartening to see today's ASX announcement on the decisions the new Board has already taken to progress down this path. The announcement of CBio's complete strategy once it has been finalised hopefully should lead to a much higher share price in due course.

From now on, I am sure we would all be grateful if the members of the Michael Monsour fan club were to redirect their posts to the ALT page.